D. Alberti

G. Wilding, J. Schiller, P. Hutson, 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.

B. Storer, J. Schiller, R. Proctor, 1991, Cancer research.

Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer

R. Mazess, G. Wilding, R. Bruskewitz, 2002 .

Biological and Clinical Effects of Intravenous Tumor Necrosis Factor-Â« Administered Three Times Weekly1

E. Borden, J. Schiller, D. Trump, 2006 .

Clinical and biologic effects of combination therapy with gamma‐interferon and tumor necrosis factor

B. Storer, E. Borden, J. Schiller, 1992, Cancer.

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

G. Wilding, D. Alberti, K. M. Kim, 2006, Investigational New Drugs.

Phase I trial of perillyl alcohol administered four times daily continuously

G. Wilding, M. Gould, H. Bailey, 2003, Cancer Chemotherapy and Pharmacology.

Phase I trial of perillyl alcohol administered

G. Wilding, M. Gould, H. Bailey, 2003 .

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

G. Wilding, J. Eickhoff, W. Schelman, 2008, Cancer Chemotherapy and Pharmacology.

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.

J. Berlin, G. Wilding, K. Tutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

J. Berlin, G. Wilding, R. Arzoomanian, 1998, Investigational New Drugs.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

G. Wilding, J. Cleary, H. Bailey, 2002, Cancer Chemotherapy and Pharmacology.

Gemcitabine, Paclitaxel, and Piritrexim: A Phase I Study

G. Wilding, H. Bailey, R. Arzoomanian, 2003, American journal of clinical oncology.

Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

J. Berlin, G. Wilding, K. Tutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole , a Calcium Signal Transduction Inhibitor : Toxicity , Bioavailability and the Effect of Food 1

J. Berlin, G. Wilding, K. Tutsch, 2002 .

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

G. Wilding, D. Spriggs, R. Mulcahy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.

J. Willson, J. Grem, D. Trump, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

R. Mazess, G. Wilding, R. Bruskewitz, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.

G. Wilding, D. Spriggs, D. Rushing, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

J. Cohen, H. Robins, K. Tutsch, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of 1-Hydroxyvitamin D 2 in the Treatment of Advanced Androgen-independent Prostate Cancer 1

G. Wilding, R. Chappell, H. Bailey, 2003 .

Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.

G. Wilding, A. Cheng, P. Hutson, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

G. Wilding, T. Mody, H. Bailey, 2011, Investigational New Drugs.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

G. Wilding, J. Kolesar, KyungMann Kim, 2013, Cancer Chemotherapy and Pharmacology.

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

G. Wilding, K. Tutsch, R. Arzoomanian, 2004, Investigational New Drugs.

Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.

J. Willson, A. Benson, S. Remick, 1989, Cancer research.

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions

G. Wilding, J. Grem, D. Spriggs, 1992, Cancer Chemotherapy and Pharmacology.

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

M. Ritter, G. Wilding, P. Hutson, 2008, Cancer Chemotherapy and Pharmacology.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days

G. Wilding, R. Hohl, S. Holstein, 2004, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

G. Wilding, J. Kolesar, R. Brundage, 2011, Cancer Chemotherapy and Pharmacology.

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.

G. Wilding, J. Kolesar, J. Eickhoff, 2011, Experimental and therapeutic medicine.

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.

G. Wilding, J. Kolesar, W. Antholine, 2008, Journal of inorganic biochemistry.

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

J. Willson, J. Grem, D. Trump, 1987, Cancer treatment reports.

A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

R. Fleming, C. Bowen, D. Alberti, 2011, Clinical colorectal cancer.

Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.

J. Koeller, J. Willson, D. Trump, 1988, Cancer research.

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion1

G. Wilding, K. Tutsch, R. Arzoomanian, 2006 .

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion 1

G. Wilding, H. Bailey, K. Tutsch, 2006 .

Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.

M. Lindstrom, G. Wilding, C. Mcginn, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.

M. Mehta, B. Badie, G. Wilding, 2004, International journal of radiation oncology, biology, physics.

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

G. Wilding, A. Tevaarwerk, Amye J. Tevaarwerk, 2009, Clinical Cancer Research.

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

D. Mahvi, G. Wilding, R. Mulcahy, 1997, Journal of the National Cancer Institute.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

D. McNeel, G. Wilding, J. Eickhoff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.

J. Berlin, G. Wilding, J. Cleary, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

D. McNeel, G. Wilding, J. Eickhoff, 2008, Clinical Cancer Research.

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Cancer Chemotherapy and Pharmacology.

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.

Andreas Friedl, G. Wilding, A. Friedl, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

J. Schiller, D. Spriggs, K. Tutsch, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

G. Wilding, M. Gould, H. Bailey, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day 1

G. Wilding, M. Gould, H. Bailey, 2000 .

Phase I clinical trial of perillyl alcohol administered daily.

G. Wilding, M. Gould, J. Stewart, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

D. DeMets, G. Wilding, H. Bailey, 2003, Investigational New Drugs.

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

J. Schiller, D. Spriggs, K. Tutsch, 1993, Investigational New Drugs.

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)

G. Wilding, D. Spriggs, H. Robins, 2004, Investigational New Drugs.

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Jens Eickhoff, Andreas Friedl, D. McNeel, 2005, Clinical Cancer Research.

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

G. Wilding, H. Bailey, K. Tutsch, 1991, Cancer research.

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

G. Wilding, D. Trump, R. Mulcahy, 1991, Cancer research.

A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia

G. Wilding, D. Spriggs, R. Love, 1999, Cancer Chemotherapy and Pharmacology.

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

G. Wilding, J. Kolesar, K. Tutsch, 2004, Clinical Cancer Research.

Phase I clinical and pharmacokinetic trial of irofulven

G. Wilding, H. Bailey, K. Tutsch, 2001, Cancer Chemotherapy and Pharmacology.

A phase I study of vorinostat in combination with bortezomib in refractory solid tumors.

G. Wilding, J. Kolesar, J. Wright, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors

G. Wilding, R. Martell, M. Gottardis, 2007, Clinical Cancer Research.

A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer.

D. McNeel, G. Wilding, J. Eickhoff, 2005, Clinical genitourinary cancer.

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

Maureen A. Smith, G. Wilding, J. Cleary, 2010, Cancer Chemotherapy and Pharmacology.

Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.

J. Willson, J. Grem, D. Trump, 1989, Cancer research.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

Pharmacokinetic and Pharmacodynamic Correlative Study of theAntisense Bcl-2 Oligonucleotide G 3139 , in Combinationwith Carboplatin and Paclitaxel , in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008 .

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

G. Wilding, J. Kolesar, J. Eickhoff, 2008, Cancer Chemotherapy and Pharmacology.

Phase I Clinical Trial of a Combination of Dipyridamole and Acivicin Based upon Inhibition of Nucleoside Salvage1

J. Willson, D. Trump, D. Tormey, 2006 .

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

Randomized , Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients withMetastatic , Androgen-Independent Prostate Cancer

G. Wilding, J. Eickhoff, S. Attia, 2008 .

Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.

M. Mehta, G. Wilding, J. Cohen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I T rial o f I ntravenous T hymidine a nd C arboplatin in P atients W ith A dvanced C ancer

M. Mehta, G. Wilding, E. Jacobson, 1999 .

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

G. Wilding, J. Kolesar, J. Eickhoff, 2014, Investigational New Drugs.

A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Journal of Clinical Oncology.

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

D. McNeel, G. Wilding, J. Eickhoff, 2008, Clinical Cancer Research.

A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

R. Fleming, C. Bowen, D. Alberti, 2011, Clinical colorectal cancer.

A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors.

G. Wilding, R. Fleming, C. Bowen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib

R. Jeraj, G. Wilding, J. Kolesar, 2008 .

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.